Medigene AG Medigene AG

Medigene AG

MDG1

Rangering i aksjer #35294
Medigene AG is a German biotechnology company primarily focused on innovating T... Medigene AG is a German biotechnology company primarily focused on innovating T cell immunotherapies to treat various cancers. Their developmental pipeline includes personalized T cell therapies, particularly T cell receptor-modified T cells, which are progressing through clinical stages to tackle significant unmet medical requirements. Additionally, the firm researches dendritic cell vaccines and T cell-specific monoclonal antibodies. Outside of its oncology efforts, Medigene is actively engaged in developing and bringing to market RhuDex for uses within hepatology and gastroenterology. A key strategic alliance exists with 2seventy bio, Inc., centered on advancing T cell receptors. The company also maintains research collaborations with the Université de Montréal and Cytovant Sciences Co. Ltd., investigating new cancer antigens for immunotherapy applications. Medigene's global presence encompasses operations across Europe, the United States, Asia, and various other international territories. Founded in 1994, the company's headquarters are located in Munich, Germany.
Aksjekurs
$0.14942078
Sist synkronisert: 2025-05-15
Markedsverdi
$3.86M
Endring (1 dag)
0.10%
Endring (1 år)
47.84%
Land
DE
Handel Medigene AG (MDG1)

Kategori

Healthcare
Historikk for aksjesplitt for Medigene AG (MDG1)
Aksjen Medigene AG (symbol: MDG1) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én MDG1-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 MDG1-aksjer.
Liste over aksjesplitt
År Splitt Multiplikator Kumulativ multiplikator
Ikke nok data for de angitte datoene.
Aksjesplitt for lignende selskaper eller konkurrenter
Selskap Antall aksjesplitt Kumulativ multiplikator Land
1 x2
US
0 -
US
1 x3
AU
0 -
NL
0 -
CH